KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Ionis Pharmaceuticals (IONS) over the last 13 years, with Q3 2025 value amounting to $2.4 billion.

  • Ionis Pharmaceuticals' Total Non-Current Liabilities rose 2689.72% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 2689.72%. This contributed to the annual value of $2.4 billion for FY2024, which is 1310.03% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Total Non-Current Liabilities of $2.4 billion as of Q3 2025, which was up 2689.72% from $2.3 billion recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Total Non-Current Liabilities registered a high of $2.4 billion during Q3 2025, and its lowest value of $1.8 billion during Q4 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $2.0 billion (2023), whereas its average is $2.1 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 1069.81% in 2024, then soared by 2689.72% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $1.8 billion in 2021, then grew by 6.98% to $2.0 billion in 2022, then rose by 6.56% to $2.1 billion in 2023, then increased by 13.1% to $2.4 billion in 2024, then increased by 0.97% to $2.4 billion in 2025.
  • Its last three reported values are $2.4 billion in Q3 2025, $2.3 billion for Q2 2025, and $2.3 billion during Q1 2025.